Study ID: ECOG E2408
Description:

3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs. Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma

Location:
Sioux Falls Region,Fargo Region,Bemidji Clinic
Principal Investigator:
Miroslaw Mazurczak MD,Preston Steen MD
Disease:
NHL (Non-Hodgkins Lymphoma)
Stage:
Phase II

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list